About Abera

Abera is dedicated to the development of novel vaccines to save lives and increase health globally.

hexa-02 copy

the company

Abera Bioscience is a platform and vaccine development company based on over 30 years of research in the medical, molecular and microbiological field. Abera was founded in 2012 as a spin-out from the Swedish protein production company Xbrane Bioscience.

Our founder and CSO, Prof. Joen Luirink is a world-leading expert on bacterial protein trafficking and membrane transport systems and his vast knowledge in the area provided the basis for Abera’s innovative vaccine delivery platform.

Abera’s novel vaccine delivery platform was first developed for the production of difficult-to-express proteins by bacteria. But when we developed the possibility to display antigenic proteins on bacterial surfaces, the idea of exploiting it for vaccine delivery was born.

our history

Since the start we have collaborated with academia and the biotech industry to develop and refine the platform. A number of experimental vaccines was designed to provide valuable proof of concept for our technology (e.g. against pneumococcal disease, chlamydia, ETEC and tuberculosis). Many collaborations have received significant financial support from EU (Horizon 2020, Eurostars and Eureka), governments and non-profit health organizations. This has enabled us to advance the technology and build our solid foundation of today.

We strongly believe that vaccines are one of the most powerful tools to save lives and increase health globally. Abera is dedicated to the development of novel vaccines and vaccine strategies to meet these ambitions.

Our mission is to develop vaccine candidates based on our novel vaccine delivery platform to late pre-clinical or early clinical phase and to find licensing partners for further development of the vaccines.

our history

Since the start we have collaborated with academia and the biotech industry to develop and refine the platform. A number of experimental vaccines was designed to provide valuable proof of concept for our technology (e.g. against pneumococcal disease, chlamydia, ETEC and tuberculosis). Many collaborations have received significant financial support from EU (Horizon 2020, Eurostars and Eureka), governments and non-profit health organizations. This has enabled us to advance the technology and build our solid foundation of today.

We strongly believe that vaccines are one of the most powerful tools to save lives and increase health globally. Abera is dedicated to the development of novel vaccines and vaccine strategies to meet these ambitions.

Our mission is to develop vaccine candidates based on our novel vaccine delivery platform to late pre-clinical or early clinical phase and to find licensing partners for further development of the vaccines.


Management TeaM

Maria Alriksson

CEO

Maria Alriksson started her career within the pharma industry and she has extensive experience in people and project management, business development, change management and marketing from different industries. Former CEO of Xbrane Bioscience.

Born: 1983
Shares in Abera: 259,214
Warrants: 45,000

Joen Luirink

CSO, Member of the Board
Prof. Luirink has more than 35 years of experience in Biochemistry and Molecular Microbiology and authored over 140 original scientific publications in peer-reviewed journals. Prof. Luirink specializes in protein trafficking in bacteria. He is currently head of the Department of Molecular Microbiology at VU University Amsterdam, and serves as the CSO of Abera.

Born: 1960
Shares in Abera: 583,332
Warrants: 25,000

Joen Luirink

CSO, Member of the Board
Prof. Luirink has more than 35 years of experience in Biochemistry and Molecular Microbiology and authored over 140 original scientific publications in peer-reviewed journals. Prof. Luirink specializes in protein trafficking in bacteria. He is currently head of the Department of Molecular Microbiology at VU University Amsterdam, and serves as the CSO of Abera.

Born: 1960 Shares in Abera: 583,332
Warrants: 25,000

hexa-03

BOARD OF DIRECTORS

Anders Ericsson

Executive Chairman of the Board

Anders Ericson has worked in several positions within the financial industry for more than 18 years. He is the owner and CEO of Smallcap.se, which is a financial communications firm specializing in life science companies.

Born: 1970
Shares in Abera: 696,490 Warrants: 25,000

Cristina Glad

Member of the Board
Cristina Glad has an Executive MBA and PhD within Biochemistry. PhD Glad has over 30 years of experience in leading positions within biotech industry, eg. As Vice president at Bioinvent. PhD Glad has extensive experience of manufacturing operations, drug development, in and out licensing of projects, regulatory authorities and financing.

Born: 1952
Shares in Abera: 0
Warrants: 25,000

Fredrik Juserius

Member of the board

Fredrik Juserius is a civil engineer with over 30 years of experience within Big Pharma in roles such as Country manager and Commercial director from e.g. GSK, Allergan and Takeda. Mr. Juserius has been responsible for in and out licensing, M&A and business development within both vaccines and cancer.

Born: 1967
Shares in Abera: 14,492 Warrants: 25,000

Joen Luirink

CSO, Member of the board

Prof. Luirink has more than 35 years of experience in Biochemistry and Molecular Microbiology and authored over 140 original scientific publications in peer-reviewed journals. Prof. Luirink specializes in protein trafficking in bacteria. He is currently head of the Department of Molecular Microbiology at VU University Amsterdam, and serves as the CSO of Abera.

Born: 1960
Shares in Abera: 583,332
Warrants: 25,000

hexa-02 copy

ADVISORY BOARD

Jan-Willem de Gier

Member of the Advisory board

Prof. de Gier is group leader at the Dept. of Biochemistry and Biophysics of Stockholm University. His work focuses on the engineering of bacteria for recombinant protein production. Prof. de Gier co-founded the successful biotech start-up Xbrane Bioscience, now Xbrane Biopharma.

Samuel Wagner

Member of the Advisory board

Prof. dr. Wagner is Professor of Infection Biology and Head of the Section of Cellular and Molecular Microbiology of the Eberhard Karls University Tübingen, Germany. He specializes in protein export pathways in pathogenic bacteria. Prof. dr. Wagner is a co-founder of Xbrane Biopharma and predecessor Xbrane Bioscience.

Marien de Jonge

Member of the Advisory board

Prof. Marien de Jonge is Head of the Section Pediatric Infectious Diseases at the Radboud University Medical Centre. Previously he held the position of Project leader at vaccine producer Nobilon (MSD). Through his role at RUMC Prof. de Jonge has been a partner to Abera on the development of a pneumococcal vaccine since 2012.

hexa-03

Career

We are continuously looking for talented people to join our journey. Do you have experience in our field, feel free to send us an open application to info@aberabio.com

We are looking for:

  • Vaccinologist
  • Immuno-oncology project manager